PD1 blockade with low-dose nivolumab in NK/T cell lymphoma failing l-asparaginase: efficacy and safety
- 975 Downloads
Extranodal natural killer (NK)/T cell lymphoma is an aggressive malignancy. Effective regimens for this lymphoma contain l-asparaginase. For patients failing l-asparaginase-containing regimens, there are no useful conventional salvage approaches . We recently reported that blockade of programmed cell death protein 1 (PD1) on effector T cells with the anti-PD1 antibody pembrolizumab was highly efficacious in NK/T cell lymphoma failing l-asparaginase .
Anti-PD1 antibodies are off-label non-reimbursed drugs for NK/T cell lymphomas. Not every patient can afford pembrolizumab. Since employing PD1 blockade as an option for NK/T cell lymphomas failing l-asparaginase, we have with informed consent treated three patients who could only afford another anti-PD1 antibody nivolumab, which if given at 40 mg (the smallest vial available) every 2 weeks (Q2W) was much cheaper than pembrolizumab.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 5.Chan TSY, Sim JPY, Kwong YL (2017). Low-dose nivolumab-induced responses in acute lymphoblastic leukaemia relapse after allogeneic haematopoietic stem cell transplantation. Ann Hematol, Jun 1 [Epub ahead of print]Google Scholar
- 6.Zhao X, Suryawanshi S, Hruska M, Feng Y, Wang X, Shen J, Vezina HE, McHenry MB, Waxman IM, Achanta A, Bello A, Roy A, Agrawal S (2017). Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors. Ann Oncol, May 17 [Epub ahead of print]Google Scholar
- 7.Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, Cauquil C, Chanson P, Collins M, Durrbach A, Ederhy S, Feuillet S, François H, Lazarovici J, Le Pavec J, De Martin E, Mateus C, Michot JM, Samuel D, Soria JC, Robert C, Eggermont A, Marabelle A (2016) Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 27(4):559–574CrossRefPubMedGoogle Scholar